priors.science/reviews/perioperative-immunotherapy-solid-tumours

Perioperative Immunotherapy Solid Tumours

The current evidence on 17 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty: how firmly the literature supports the claim as stated.

17claims tracked

396primary papers reviewed

23 Oct 2026latest evidence review

6 Established · 7 Likely · 2 Uncertain · 2 Doubtful | four-reviewer panel · PICO Framework

ClaimStandingEvidence certaintyCorpus

Adjuvant pembrolizumab in stage III melanomaMelanomaEstablished95%27

Adjuvant nivolumab disease-free survival in bladder cancerBladderEstablished90%29

Perioperative nivolumab event-free survival in non-small cell lung cancerNsclcEstablished90%29

KEYNOTE-522 pathological complete response and event-free survival in triple-negative breast cancerTnbcEstablished90%29

Adjuvant pembrolizumab in stage IIB-C melanomaMelanomaEstablished88%33

Pathological complete response as surrogate for non-small cell lung cancer immune checkpoint inhibitor therapyNsclcEstablished86%30

Adjuvant pembrolizumab disease-free survival in non-small cell lung cancerNsclcLikely84%27

Adjuvant pembrolizumab disease-free and overall survival in renal cell carcinomaRCCLikely84%27

Perioperative immune checkpoint inhibitor expansion in muscle-invasive bladder cancerBladderLikely83%26

Neoadjuvant dual immune checkpoint inhibitor pathological complete response in microsatellite instability-high colon cancerMsi ColonLikely82%24

Microsatellite instability-high colon cancer immune checkpoint inhibitor surrogate biomarkerMsi ColonLikely82%23

Pathological complete response surrogate for triple-negative breast cancer immune checkpoint inhibitor therapyTnbcLikely80%26

Perioperative pembrolizumab event-free and overall survival in non-small cell lung cancerNsclcLikely78%30

Adjuvant immune checkpoint inhibitor benefit is agent-specific in renal cell carcinomaRCCUncertain60%29

Adjuvant nivolumab benefit independent of PD-L1 statusBladderUncertain56%29thin basis

Immune checkpoint inhibitor neoadjuvant benefit inconsistent in triple-negative breast cancerTnbcDoubtful40%27

Adjuvant nivolumab vs ipilimumab in melanomaMelanomaDoubtful38%33

Track Perioperative Immunotherapy Solid Tumours.

These claims are re-checked against new research as it is published. Track this topic for the full review, including each claim’s challenge and the papers behind it.

Track this topic →

Standing: what the evidence certainty means

Established≥ 85%Strong, consistent evidence. Unlikely to change.

Likely70–84%Well supported, with some gaps or indirect evidence.

Uncertain50–69%Mixed or limited evidence. Genuinely open.

Doubtful30–49%Little support; the weight of evidence leans against it.

Refuted< 30%The evidence contradicts it. Confidently false as stated.

A standing changes only when the score moves past a boundary by more than 4 points, the re-scoring noise floor; a score within 4 points of a boundary keeps its previous standing.